BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 16620554)

  • 1. [Study on the mechanisms of imatinib-resistance of cancer stem-like cells in K562/Vp16 cell line].
    Song YP; Fang BJ; Wei XD; Zheng S
    Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):669-73. PubMed ID: 16620554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Establishment of an imatinib resistant cell line K562/G01 and its characterization].
    Qi J; Peng H; Gu ZL; Liang ZQ; Yang CZ
    Zhonghua Xue Ye Xue Za Zhi; 2004 Jun; 25(6):337-41. PubMed ID: 15308010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of phenylhexyl isothiocyanate on drug-resistance to imatinib in K562/G01 cell line].
    Wu RJ; Huang YQ; Ma XD
    Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):149-52. PubMed ID: 23611223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-cell analysis of K562 cells: an imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein.
    Karimiani EG; Marriage F; Merritt AJ; Burthem J; Byers RJ; Day PJ
    Exp Hematol; 2014 Mar; 42(3):183-191.e5. PubMed ID: 24269846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate.
    Giuntoli S; Tanturli M; Di Gesualdo F; Barbetti V; Rovida E; Dello Sbarba P
    Haematologica; 2011 Feb; 96(2):204-12. PubMed ID: 21071498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells.
    Peng XX; Tiwari AK; Wu HC; Chen ZS
    Chin J Cancer; 2012 Feb; 31(2):110-8. PubMed ID: 22098951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
    Mencalha AL; CorrĂȘa S; Salles D; Du Rocher B; Santiago MF; Abdelhay E
    BMC Cancer; 2014 Nov; 14():866. PubMed ID: 25417721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
    Wei YL; Liang Y; Xu L; Zhao XY
    Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
    Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia.
    Zong Y; Zhou S; Sorrentino BP
    Leukemia; 2005 Sep; 19(9):1590-6. PubMed ID: 16001089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.
    Mukai M; Che XF; Furukawa T; Sumizawa T; Aoki S; Ren XQ; Haraguchi M; Sugimoto Y; Kobayashi M; Takamatsu H; Akiyama S
    Cancer Sci; 2003 Jun; 94(6):557-63. PubMed ID: 12824882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
    Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
    Mahon FX; Belloc F; Lagarde V; Chollet C; Moreau-Gaudry F; Reiffers J; Goldman JM; Melo JV
    Blood; 2003 Mar; 101(6):2368-73. PubMed ID: 12609962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
    Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
    Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells.
    Baran Y; Ural AU; Gunduz U
    Hematology; 2007 Dec; 12(6):497-503. PubMed ID: 17852433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells.
    Nambu T; Araki N; Nakagawa A; Kuniyasu A; Kawaguchi T; Hamada A; Saito H
    Cancer Sci; 2010 Jan; 101(1):137-42. PubMed ID: 19843070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells.
    Baran Y; Salas A; Senkal CE; Gunduz U; Bielawski J; Obeid LM; Ogretmen B
    J Biol Chem; 2007 Apr; 282(15):10922-34. PubMed ID: 17303574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.
    Ju DS; Kim MJ; Bae JH; Song HS; Chung BS; Lee MK; Kang CD; Lee HS; Kim DW; Kim SH
    Cancer Lett; 2007 Jul; 252(1):75-85. PubMed ID: 17223257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
    Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.